The results of NASH could be very important. We had an indication that LL produced a benefit. A confirmation (does not matter how strong), just a confirmation that a trial is granted should be an enormous catalyzer.

The graph below shows a forecast if the annual income for NASH backbone treatment only (complementary treatments, targeting fibrosis at start, have a similar value).

http://www.nashbiotechs.com/nash-biotech-anal...h-list.php

Some important point here:

• There is no current treatment (graph is based on possibilities ), please note that 2022 barely shows… If there is one indication that any company would like to be able to address is this one (apart, of course, from Oncology)
• There is no SOC, so the first companies will have an easier time getting BTD (currently only Ocaliva-INTERCEPT and IMM124E-IMMURON have this designation)
• The market in very large (to say the least)
• There is a humongous NASH epidemic approaching, any company in this field (with a drug) will be singing to the bank
https://www.gastrojournal.org/article/S0016-5...6/fulltext
• We are not there (yet), however just being in P2 in this space would demand an immediate forecast potential of Billions (with B ).
• This is a good time to enter the race






So, pleaseeee give us the 700mg results pronto !!!!